keyword
MENU ▼
Read by QxMD icon Read
search

recurrent clostridium difficile

keyword
https://www.readbyqxmd.com/read/29450831/comparison-of-different-strategies-for-providing-fecal-microbiota-transplantation-to-treat-patients-with-recurrent-clostridium-difficile-infection-in-two-english-hospitals-a-review
#1
REVIEW
Simon D Goldenberg, Rahul Batra, Ian Beales, Jonathan Leith Digby-Bell, Peter Miles Irving, Lee Kellingray, Arjan Narbad, Ngozi Franslem-Elumogo
Fecal microbiota transplant (FMT) has emerged as a highly efficacious treatment for difficult cases of refractory and/or recurrent Clostridium difficile infection (CDI). There have been many well-conducted randomized controlled trials and thousands of patients reported in case series that describe success rates of approximately 90% following one or more FMT. Although the exact mechanisms of FMT have yet to be fully elucidated, replacement or restoration of a 'normal' microbiota (or at least a microbiota resembling those who have never had CDI) appears to have a positive effect on the gut dysbiosis that is thought to exist in these patients...
February 15, 2018: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/29450212/fecal-microbiota-transplant-for-refractory-clostridium-difficile-infection-interrupts-25-year-history-of-recurrent-urinary-tract-infections
#2
Tiffany Wang, Colleen S Kraft, Michael H Woodworth, Tanvi Dhere, Molly E Eaton
No abstract text is available yet for this article.
February 2018: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/29447696/strain-tracking-reveals-the-determinants-of-bacterial-engraftment-in-the-human-gut-following-fecal-microbiota-transplantation
#3
Christopher S Smillie, Jenny Sauk, Dirk Gevers, Jonathan Friedman, Jaeyun Sung, Ilan Youngster, Elizabeth L Hohmann, Christopher Staley, Alexander Khoruts, Michael J Sadowsky, Jessica R Allegretti, Mark B Smith, Ramnik J Xavier, Eric J Alm
Fecal microbiota transplantation (FMT) from healthy donor to patient is a treatment for microbiome-associated diseases. Although the success of FMT requires donor bacteria to engraft in the patient's gut, the forces governing engraftment in humans are unknown. Here we use an ongoing clinical experiment, the treatment of recurrent Clostridium difficile infection, to uncover the rules of engraftment in humans. We built a statistical model that predicts which bacterial species will engraft in a given host, and developed Strain Finder, a method to infer strain genotypes and track them over time...
February 14, 2018: Cell Host & Microbe
https://www.readbyqxmd.com/read/29446866/tacrolimus-concentration-to-dose-ratio-in-solid-organ-transplant-patients-treated-with-fecal-microbiota-transplantation-for-recurrent-clostridium-difficile-infection
#4
Michael H Woodworth, Colleen S Kraft, Erika J Meredith, Aneesh K Mehta, Tiffany Wang, Yafet T Mamo, Tanvi Dhere, Kaitlin L Sitchenko, Rachel E Patzer, Rachel J Friedman-Moraco
Fecal microbiota transplantation (FMT) is increasingly being performed for Clostridium difficile infection in solid organ transplant patients; however, little is known about the potential pharmacokinetic or pharmacomicrobial effects this may have on tacrolimus levels. We reviewed the medical records of 10 solid organ transplant patients from September 2012 - December 2016 who were taking tacrolimus at time of FMT for recurrent Clostridium difficile infection. We compared the differences in tacrolimus concentration / dose ratio (C/D ratio) three months prior to FMT vs three months after FMT...
February 15, 2018: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29441500/the-epidemiology-of-clostridium-difficile-infection-in-japan-a-systematic-review
#5
REVIEW
Thomas V Riley, Tomomi Kimura
To increase understanding of the epidemiology, risks, consequences and resource utilization of Clostridium difficile infection (CDI) in Japan, a systematic literature review was undertaken of relevant publications from January 2006 to November 2017. Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and methods, 55 articles met the criteria for full review. The majority (58%) of studies were from a single site, with the most recent data from 2015. The incidence, reported prevalence and recurrence rate of CDI in Japan were 0...
February 13, 2018: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/29428498/the-role-of-gut-microbiota-in-clostridium-difficile-infection
#6
REVIEW
Michael Samarkos, Elpida Mastrogianni, Olga Kampouropoulou
Clostridium difficile infection has emerged as a major health problem. Because it is a spore-forming microorganism, C. difficile is difficult to eradicate and recurrences of the infection are frequent. The strong association of CDI with prior use of antibiotics led to the recognition that disturbances in the gut microbiota apparently plays a central role in CDI. Except for antibiotics, several other risk factors for CDI have been recognised, such as advanced age and use of proton pump inhibitors. The common characteristic of these factors is that they are associated with changes in the composition of gut microbiota...
February 7, 2018: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/29426057/inflammatory-bowel-disease-and-clostridium-difficile-infection-contrasting-views-of-international-clinical-professionals
#7
Andreas Stallmach, Veli-Jukka Anttila, Markus Hell, Simon Gwynn, Paloma Merino-Amador, Nicola Petrosillo, Zdenek Ráčil, Tim Warren, Christoph Wenisch, Mark Wilcox
INTRODUCTION:  In patients with inflammatory bowel disease (IBD), Clostridium difficile infection (CDI) is a risk factor for both morbidity and mortality. Currently, appropriate management is unclear. Guidance on best practice in the diagnosis and treatment of CDI in IBD patients is therefore needed. METHODS:  A multidisciplinary group of clinicians involved in the treatment of patients with IBD and CDI developed 27 consensus statements. Respondents were asked to rate their agreement with each statement using a 4-point Likert scale...
February 9, 2018: Zeitschrift Für Gastroenterologie
https://www.readbyqxmd.com/read/29422809/fecal-microbiota-transplantation-for-recurrent-clostridium-difficile-infection-in-a-patient-with-ulcerative-colitis
#8
Kosaku Nanki, Shinta Mizuno, Katsuyoshi Matsuoka, Keiko Ono, Shinya Sugimoto, Hiroki Kiyohara, Mari Arai, Moeko Nakashima, Kozue Takeshita, Keiichiro Saigusa, Mitsutoshi Senoh, Tadashi Fukuda, Makoto Naganuma, Haru Kato, Wataru Suda, Masahira Hattori, Takanori Kanai
Fecal microbiota transplantation (FMT) has been reported as a safe and effective therapy in patients with refractory and recurrent Clostridium difficile infection (CDI). FMT has also been reported as a promising therapy in patients with ulcerative colitis (UC). Both, CDI and UC, are believed to be caused by dysbiosis, such as altered compositions or decreased diversity of the intestinal microbiota. This report describes a patient with UC in remission with a second recurrent episode of CDI, who was treated with FMT...
January 2018: Intestinal Research
https://www.readbyqxmd.com/read/29411989/fecal-microbiota-transplantation-in-refractory-or-recurrent-clostridium-difficile-infection-a-real-life-experience-in-a-non-academic-center
#9
Ana Ponte, Rolando Pinho, Margarida Mota, Joana Silva, Nuno Vieira, Rosa Oliveira, Jaime Rodrigues, Mafalda Sousa, Isabel Sousa, João Carvalho
AIM: this study aimed to describe the efficacy and safety of fecal microbiota transplantation (FMT) for the treatment of refractory and recurrent Clostridium difficile infection (CDI). METHODS: this was an observational study of patients with refractory or recurrent CDI treated with FMT between June 2014 and January 2017. Primary and secondary outcomes were the resolution of diarrhea without CDI recurrence within two months after one or more FMT. A descriptive analysis was performed...
February 7, 2018: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/29409575/bezlotoxumab-for-the-prevention-of-clostridium-difficile-recurrence
#10
Elias B Chahine, Jonathan C Cho, Marylee V Worley
OBJECTIVE: To review the pharmacology, pharmacokinetics, pharmacodynamics, clinical efficacy, tolerability, dosing, and administration of bezlotoxumab (BEZ), as well as its place in the prevention of Clostridium difficile infection (CDI) recurrence. DATA SOURCES: A search of PubMed and Google Scholar using the terms "bezlotoxumab," "CDB1," "MDX-1388," and "MK-6072" was performed. The manufacturer's website was also reviewed to further identify relevant information...
February 1, 2018: Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists
https://www.readbyqxmd.com/read/29407296/oral-vancomycin-monotherapy-versus-combination-therapy-in-solid-organ-transplant-recipients-with-uncomplicated-clostridium-difficile-infection-a-retrospective-cohort-study
#11
G B Korayem, K Eljaaly, K R Matthias, T T Zangeneh
INTRODUCTION: Solid organ transplant (SOT) recipients are at high risk of Clostridium difficile infection (CDI) and CDI recurrence due to their suppressed immune systems and antibiotic exposure. A combination of metronidazole and oral vancomycin is often prescribed for SOT recipients with uncomplicated CDI despite any clinical practice guidelines supporting the need for combination therapy. This study aims to compare the CDI recurrence rates of metronidazole/vancomycin combination therapy to oral vancomycin monotherapy in SOT recipients after a first episode of uncomplicated CDI...
January 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29403263/bezlotoxumab-an-emerging-monoclonal-antibody-therapy-for-prevention-of-recurrent-clostridium-difficile-infection
#12
REVIEW
Bhagyashri D Navalkele, Teena Chopra
Clostridium difficile infection (CDI) is the most common health care-acquired infection associated with high hospital expenditures. The incidence of subsequent recurrent CDI increases with prior episodes of CDI, 15%-35% risk after primary CDI to 35%-65% risk after the first recurrent episode. Recurrent CDI is one of the most challenging and a very difficult to treat infections. Standard guidelines provide recommendations on treatment of primary CDI. However, treatment choices for recurrent CDI are limited. Recent research studies have focused on the discovery of newer alternatives for prevention of recurrent CDI targeting prime virulence factors involved in C...
2018: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/29393522/derivation-and-validation-of-a-clostridium-difficile-infection-recurrence-prediction-rule-in-a-national-cohort-of-veterans
#13
Kelly R Reveles, Eric M Mortensen, Jim M Koeller, Kenneth A Lawson, Mary Jo V Pugh, Sarah A Rumbellow, Jacqueline R Argamany, Christopher R Frei
STUDY OBJECTIVE: Prior studies have identified risk factors for recurrent Clostridium difficile infection (CDI), but few studies have integrated these factors into a clinical prediction rule that can aid clinical decision making. The objective of this study was to derive and validate a CDI recurrence prediction rule to identify patients at risk for first recurrence in a national cohort of veterans. DESIGN: Retrospective cohort study. DATA SOURCE: Veterans Affairs Informatics and Computing Infrastructure...
February 2, 2018: Pharmacotherapy
https://www.readbyqxmd.com/read/29385143/longitudinal-microbiome-analysis-of-single-donor-fecal-microbiota-transplantation-in-patients-with-recurrent-clostridium-difficile-infection-and-or-ulcerative-colitis
#14
Michael Mintz, Shanawaj Khair, Suman Grewal, Joseph F LaComb, Jiyhe Park, Breana Channer, Ramona Rajapakse, Juan Carlos Bucobo, Jonathan M Buscaglia, Farah Monzur, Anupama Chawla, Jie Yang, Charlie E Robertson, Daniel N Frank, Ellen Li
BACKGROUND: Studies of colonoscopic fecal microbiota transplant (FMT) in patients with recurrent CDI, indicate that this is a very effective treatment for preventing further relapses. In order to provide this service at Stony Brook University Hospital, we initiated an open-label prospective study of single colonoscopic FMT among patients with ≥ 2 recurrences of CDI, with the intention of monitoring microbial composition in the recipient before and after FMT, as compared with their respective donor...
2018: PloS One
https://www.readbyqxmd.com/read/29383671/immunization-strategies-against-clostridium-difficile
#15
Jean-François Bruxelle, Séverine Péchiné, Anne Collignon
C. difficile infection (CDI) is an important healthcare- but also community-associated disease. CDI is considered a public health threat and an economic burden. A major problem is the high rate of recurrences. Besides classical antibiotic treatments, new therapeutic strategies are needed to prevent infection, to treat patients and prevent recurrences. If fecal transplantation has been recommended to treat recurrences, another key approach is to restore immunity against C. difficile and its virulence factors...
2018: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29383670/faecal-microbiota-transplantation-as-emerging-treatment-in-european-countries
#16
Marcello Maida, James Mcilroy, Gianluca Ianiro, Giovanni Cammarota
Clostridium difficile infection (CDI) is one of the most common healthcare-associated infections in the world and is a leading cause of morbidity and mortality in hospitalized patients.Although several antibiotics effectively treat CDI, some individuals do not respond to these drugs and may be cured by transplanting stool from healthy donors. This procedure, termed Faecal Microbiota Transplantation (FMT), has demonstrated remarkable efficacy as a treatment for recurrent CDI.FMT has also been investigated in other diseases and disorders where perturbations to the gut microbiota have been theorized to play a causative role in pathogenesis and severity, such as inflammatory bowel disease (IBD)...
2018: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29383667/european-practice-for-cdi-treatment
#17
Fidelma Fitzpatrick, Mairead Skally, Melissa Brady, Karen Burns, Christopher Rooney, Mark H Wilcox
Clostridium difficile infection (CDI) remains a significant cause of morbidity and mortality worldwide. Historically, two antibiotics (metronidazole and vancomycin) and a recent third (fidaxomicin) have been used routinely for CDI treatment; convincing data are now available showing that metronidazole is the least efficacious agent. The European Society of Clinical Microbiology and Infectious Diseases CDI treatment guidelines outline the treatment options for a variety of CDI clinical scenarios, including use of the more traditional anti-CDI therapies (e...
2018: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29383666/clostridium-difficile-biofilm
#18
Claudia Vuotto, Gianfranco Donelli, Anthony Buckley, Caroline Chilton
Clostridium difficile infection (CDI) is an important healthcare-associated disease worldwide, mainly occurring after antimicrobial therapy. Antibiotics administered to treat a number of infections can promote C. difficile colonization of the gastrointestinal tract and, thus, CDI. A rise in multidrug resistant clinical isolates to multiple antibiotics and their reduced susceptibility to the most commonly used antibiotic molecules have made the treatment of CDI more complicated, allowing the persistence of C...
2018: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29383664/comparative-genomics-of-clostridium-difficile
#19
Sandra Janezic, Julian R Garneau, Marc Monot
Clostridium difficile, a gram-positive spore-forming anaerobic bacterium, has rapidly emerged as the leading cause of nosocomial diarrhoea in hospitals. The availability of genome sequences in large numbers, mainly due to the use of next-generation sequencing methods, have undoubtedly shown their immense advantages in the determination of the C. difficile population structure. The implementation of fine-scale comparative genomic approaches have paved the way to global transmission and recurrence studies, but also more targeted studies such as the PaLoc or the CRISPR/Cas systems...
2018: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29383660/economic-burden-of-clostridium-difficile-infection-in-european-countries
#20
Elena Reigadas Ramírez, Emilio Santiago Bouza
Clostridium difficile infection (CDI) remains a considerable challenge to health care systems worldwide. Although CDI represents a significant burden on healthcare systems in Europe, few studies have attempted to estimate the consumption of resources associated with CDI in Europe. The reported extra costs attributable to CDI vary widely according to the definitions, design, and methodologies used, making comparisons difficult to perform. In this chapter, the economic burden of healthcare facility-associated CDI in Europe will be assessed, as will other less explored areas such as the economic burden of recurrent CDI, community-acquired CDI, pediatric CDI, and CDI in outbreaks...
2018: Advances in Experimental Medicine and Biology
keyword
keyword
115341
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"